RA Capital Management L.P. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

RA Capital Management L.P. cut its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,184,711 shares of the company's stock after selling 332,548 shares during the quarter. RA Capital Management L.P. owned approximately 8.72% of iTeos Therapeutics worth $32,516,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ITOS. Candriam S.C.A. bought a new stake in iTeos Therapeutics in the second quarter valued at $7,558,000. Clearline Capital LP bought a new stake in shares of iTeos Therapeutics during the 2nd quarter valued at about $2,328,000. Algert Global LLC increased its position in shares of iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock valued at $2,615,000 after buying an additional 122,730 shares during the period. Dimensional Fund Advisors LP raised its stake in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock worth $13,481,000 after buying an additional 117,159 shares in the last quarter. Finally, Readystate Asset Management LP lifted its holdings in iTeos Therapeutics by 97.2% in the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company's stock worth $1,734,000 after buying an additional 83,700 shares during the period. Hedge funds and other institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Stock Down 1.8 %

Shares of iTeos Therapeutics stock traded down $0.15 on Thursday, reaching $8.04. The company's stock had a trading volume of 124,528 shares, compared to its average volume of 443,830. iTeos Therapeutics, Inc. has a 52 week low of $7.54 and a 52 week high of $18.75. The firm's fifty day simple moving average is $9.01 and its two-hundred day simple moving average is $13.42. The company has a market capitalization of $293.70 million, a price-to-earnings ratio of -2.60 and a beta of 1.37.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, research analysts predict that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall acquired 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares of the company's stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 12.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ITOS has been the subject of several research reports. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an "overweight" rating and a $31.00 target price for the company. JPMorgan Chase & Co. decreased their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating for the company in a report on Monday, August 12th. HC Wainwright restated a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Friday, November 15th. Finally, Wedbush reiterated an "outperform" rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research note on Tuesday, November 12th.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.